Zerafil (omalizumab biosimilar) / CinnaGen - LARVOL DELTA

Efficacy and safety of a proposed omalizumab biosimilar compared to the reference product in the management of uncontrolled moderate-to-severe allergic asthma: a multicenter, phase III, randomized, double-blind, equivalency clinical trial. (PubMed, Front Immunol) - P3 | "In this phase III clinical trial P043 (Zerafil®, CinnaGen, Iran) efficacy, safety, and immunogenicity were compared with Xolair® (the originator omalizumab)...There was no significant difference in other efficacy and safety parameters. www.clinicaltrials.gov (NCT05813470) and www.IRCT.ir (IRCT20150303021315N20)."

Clinical • Journal • P3 data • Asthma • Immunology • Pain • Pulmonary Disease • Respiratory Diseases